Controversy over a $324 million deal between Brazil and Bharat Biotech – for the import of 20 million Covaxin doses – continues to grow, with reports from the South American country saying its national health regulator never gave the vaccine an EUA.
Hyderabad-based Bharat Biotech has just published the trial data for its COVID-19 vaccine, Covaxin, which claims the India-made vaccine to be 77.8% effective against the coronavirus. The vaccine was found to have 93% efficacy against severe cases of COVID-19 and 63% efficacy against asymptomatic transmission. Trial data also indicated that the vaccine was effective against the Delta variant of the virus. “BBV152 conferred 65.2% protection against the SARS CoV 2 Variant of Concern, B.1.617.2 (Delta),” the release from Bharat Biotech said.
#Brazil’s top prosecutor agreed on Friday to request an #investigation of President Jair #Bolsonaro for dereliction of duty in the process of procuring an Indian Covid-19 vaccine. The president has been caught up in allegations of irregularities surrounding the 1.6 billion reais ($316 million) contract signed in February for 20 million doses with a Brazilian intermediary for the vaccine’s maker, Bharat Biotech.The government suspended the contract on Tuesday after a Senate commission raised suspicions of overpricing and corruption. FRANCE 24’s Tim Vickery for the latest.Subscribe to France 24 now:http://f24.my/youtubeENFRANCE 24 live news stream: all the latest news 24/7http://f24.my/YTliveENVisit our website:http://www.france24.comSubscribe to our YouTube channel:http://f24.my/youtubeENLike us on Facebook:https://www.facebook.com/FRANCE24.EnglishFollow us on Twitter:https://twitter.com/France24_en
The National Institute of Health (NIH) in the United States has found that Bharat Biotech’s COVAXIN vaccine generates antibodies that effectively neutralize both Alpha and Delta variants of COVID-19. The top health research institute said that an adjuvant developed with funding from the NIH has contributed to the success of the “highly efficacious” COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere.
On Wednesday, India’s indigenous COVID vaccine ‘Covaxin’ manufacturer Bharat Biotech has submitted its phase-3 clinical trial results to the World Health Organization (WHO) for clearance. Hyderabad-based Bharat Biotech’s pre-submission meeting has been scheduled on June 23 for evaluation of the WHO’s Emergency Use Listing (EUL) of its indigenous COVID-19 vaccine Covaxin.
The Drugs Controller General of India (DCGI) on Thursday approved Phase 2 and 3 clinical trial of Bharat Biotech’s COVAXIN vaccine in the age group of 2 to 18 years, informed the Ministry of Health and Family Welfare. Bharat Biotech will conduct trials in 525 healthy volunteers. “In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28,” it said.
Subject Expert Committee (SEC) gave nod to Bharat Biotechs Covaxin for phase 2 and 3 human clinical trials on 2 to 18 years. In the ongoing vaccination drive in India, the Covaxin is being used in adults. Covaxin is one of the two vaccines being manufactured in India currently and has been developed by Bharat Biotech.